Literature DB >> 11836128

Phenolic modification as an approach to improve the pharmacology of the 3-acyloxy-2-benzylpropyl homovanillic amides and thioureas, a promising class of vanilloid receptor agonists and analgesics.

Jeewoo Lee1, Jiyoun Lee, Myung-Sim Kang, Kang-Pil Kim, Suk-Jae Chung, Peter M Blumberg, Jung-Bum Yi, Young Ho Park.   

Abstract

In order to improve the analgesic activity and pharmacokinetics of thioureas 2 and 3, which we previously developed as potent vanilloid receptor (VR) agonists, we prepared and characterized phenolic modifications of them and of their amide surrogates (7, 8). The aminoethyl analogue of the amide template 13 was a potent analgesic with an EC50=0.96 microg/kg in the AA-induced writhing test and with better in vivo stability than the parent phenol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836128     DOI: 10.1016/s0968-0896(01)00387-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1.

Authors:  Á Czikora; E Lizanecz; P Bakó; I Rutkai; F Ruzsnavszky; J Magyar; R Pórszász; T Kark; A Facskó; Z Papp; I Édes; A Tóth
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  The SAR analysis of TRPV1 agonists with the α-methylated B-region.

Authors:  Yongsung Cho; Myeong Seop Kim; Ho Shin Kim; Jihyae Ann; Jiyoun Lee; Larry V Pearce; Vladimir A Pavlyukovets; Matthew A Morgan; Peter M Blumberg; Jeewoo Lee
Journal:  Bioorg Med Chem Lett       Date:  2012-06-23       Impact factor: 2.823

3.  Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist.

Authors:  Keld Fosgerau; Uno J Weber; Jacob W Gotfredsen; Magdalena Jayatissa; Carsten Buus; Niels B Kristensen; Mogens Vestergaard; Peter Teschendorf; Andreas Schneider; Philip Hansen; Jakob Raunsø; Lars Køber; Christian Torp-Pedersen; Charlotte Videbaek
Journal:  BMC Cardiovasc Disord       Date:  2010-10-09       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.